company background image
3KY logo

Hansoh Pharmaceutical Group DB:3KY Stock Report

Last Price

€2.26

Market Cap

€13.7b

7D

3.7%

1Y

37.8%

Updated

02 Dec, 2024

Data

Company Financials +

Hansoh Pharmaceutical Group Company Limited

DB:3KY Stock Report

Market Cap: €13.7b

3KY Stock Overview

An investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People’s Republic of China. More details

3KY fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance5/6
Financial Health5/6
Dividends3/6

Hansoh Pharmaceutical Group Company Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hansoh Pharmaceutical Group
Historical stock prices
Current Share PriceHK$2.26
52 Week HighHK$2.66
52 Week LowHK$1.32
Beta0.65
11 Month Change11.88%
3 Month Change-2.59%
1 Year Change37.80%
33 Year Change25.56%
5 Year Change-18.12%
Change since IPO20.79%

Recent News & Updates

Recent updates

Shareholder Returns

3KYDE PharmaceuticalsDE Market
7D3.7%-1.5%1.5%
1Y37.8%-19.6%8.8%

Return vs Industry: 3KY exceeded the German Pharmaceuticals industry which returned -19.6% over the past year.

Return vs Market: 3KY exceeded the German Market which returned 7.8% over the past year.

Price Volatility

Is 3KY's price volatile compared to industry and market?
3KY volatility
3KY Average Weekly Movement9.6%
Pharmaceuticals Industry Average Movement6.9%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.9%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 3KY's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 3KY's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
19959,099Huijuan Zhongwww.hspharm.com

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-tumor, anti-infection, central nervous system diseases, oncology, metabolic and autoimmune diseases, etc. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Hengmu, Mailingda, Hengsen, XINYUE, Saint Luolai, Fulaimei, Pulaitan, Tanneng, Ameining, Oulanning, Ruibote, Fulaidi, Fulairui, and Puruian tablets. The company serves pharmaceutical product distributors.

Hansoh Pharmaceutical Group Company Limited Fundamentals Summary

How do Hansoh Pharmaceutical Group's earnings and revenue compare to its market cap?
3KY fundamental statistics
Market cap€13.74b
Earnings (TTM)€617.20m
Revenue (TTM)€1.58b

22.3x

P/E Ratio

8.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
3KY income statement (TTM)
RevenueCN¥12.10b
Cost of RevenueCN¥1.09b
Gross ProfitCN¥11.01b
Other ExpensesCN¥6.30b
EarningsCN¥4.71b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.79
Gross Margin91.01%
Net Profit Margin38.97%
Debt/Equity Ratio0.1%

How did 3KY perform over the long term?

See historical performance and comparison

Dividends

2.0%

Current Dividend Yield

40%

Payout Ratio